NEI Research News

NEI research fellow Nathan Hotaling, PhD, has been awarded a $65,000 grant from the Knights Templar Eye Foundation to develop a stem cell-based system to study Best disease, a genetic disorder that can cause progressive vision loss.

A pain medicine that potently activates a receptor vital to a healthy retina appears to help preserve vision in an animal model of severe retinal degeneration, NEI-funded scientists at Medical College of Georgia at Augusta University report.

Retinas from our earliest vertebrate ancestors had cone-like photoreceptors, presumably allowing them to see in daylight, but little ability to see at night.

People with type 2 diabetes who intensively controlled their blood sugar level were found to have cut their risk of diabetic retinopathy in half.

In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better after five years of treatment with anti-VEGF drugs that are injected into the eye.

David Watson has worn glasses to correct nearsightedness the majority of his life, and had his vision checked regularly to make sure his prescription was up to date.

Researchers at the University of Pennsylvania showed that in a form of canine blindness retinal cells continue to differentiate for a period of time early in a dog’s life before overwhelming cell death caused the retina to degenerate.

Researchers at LSU Health New Orleans have shown that a protein critical to the body’s ability to remove waste products from the brain and retina is diminished in age-related macular degeneration.

A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab).

Our eyes are especially demanding when it comes to energy: Along with our brain, they require a substantial amount of power to keep them functioning and healthy.